Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments

<div>In vivo MR imaging of GPC3-expressing tumors via L5 peptide-guided two-step pretargeting approach. The tumor cells were implanted subcutaneously in the back of animals. On 1 hour postinjection T2WI image, xenografts (arrowheads) showed significant signal decrease in the pretargeting group (PT) but not in the nonpretargeting (NT) or control group.</div>

Contrast Media & Molecular Imaging

fig7

Figure 7

Figure 7: Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments 

Figure 7 | Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments 